Here, we investigated ABT-737 and Purvalanol A asa potential drug pairing for pediatric AML and described the developmentof CD33-targeted polymeric nanoparticles (NPs) to enable their simultaneoustargeted codelivery. This evidence concerns the gene CD33 and acute myeloid leukemia.